Zacks Research Upgrades Silexion Therapeutics (NASDAQ:SLXN) to Hold

Silexion Therapeutics (NASDAQ:SLXN) was upgraded by research analysts at Zacks Research to a “hold” rating in a report issued on Tuesday,Zacks.com reports.

Other equities analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Wednesday, October 8th. Litchfield Hills Research assumed coverage on Silexion Therapeutics in a research report on Monday. They issued a “buy” rating on the stock. Finally, Wall Street Zen upgraded Silexion Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Saturday, November 15th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $75.00.

Silexion Therapeutics Stock Performance

Shares of NASDAQ:SLXN opened at $2.57 on Tuesday. The business has a 50-day moving average of $3.04 and a two-hundred day moving average of $6.95. The firm has a market capitalization of $8.04 million, a PE ratio of -0.23 and a beta of -0.06. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.97 and a quick ratio of 3.97. Silexion Therapeutics has a 12 month low of $2.13 and a 12 month high of $51.75.

Silexion Therapeutics (NASDAQ:SLXN) last issued its earnings results on Wednesday, November 12th. The company reported ($2.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.40) by $0.52.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.